AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019

May 8, 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--May 8, 2019--ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 at 3:15 p.m. PT at the Encore Hotel in Las Vegas, NV.

The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; miransertib (ARQ 092), a potent and selective inhibitor of the AKT serine/threonine kinase, planned to initiate registrational trial cohorts in Proteus syndrome and PROS in 2019, and in phase 1b in combination with the hormonal therapy, anastrozole, in patients with advanced endometrial cancer; ARQ 751, a next generation highly potent and selective AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA in collaboration with Basilea and Sinovant. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005079/en/

CONTACT: Corporate Contact:

Kathleen Farren

Investor Relations &

Executive Assistant to the CFO

ir@arqule.comMedia Contact:

Cait Williamson, Ph.D.

LifeSci Public Relations (646) 751-4366

cait@lifescipublicrelations.com

www.ArQule.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL FDA

SOURCE: ArQule, Inc.

Copyright Business Wire 2019.

PUB: 05/08/2019 07:00 AM/DISC: 05/08/2019 07:01 AM

http://www.businesswire.com/news/home/20190508005079/en